We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
AskQtyOrders

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

-
-
arrow

LOWER/UPPER CIRCUITS

-
-
arrow
Zydus Lifesciences Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 18.55%, in the last year to ₹23,511 Cr. Its sector's average revenue growth for the last fiscal year was 10.77%.
noteAnnual Net Profit,rose 17.26% in the last year to ₹4,525.5 Cr. Its sector's average net profit growth for the last fiscal year was 39.17%.
notePrice to Earning Ratio,is 21.9, lower than its sector PE ratio of 42.65.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 23.75%
Net profit growth 5Y CAGR : 15.79%

STOCK RETURNS

info
Versus Nifty 50
1 w
+1.37%
vs
-0.37%
1 mth
+7.45%
vs
+3.71%
3 mth
+10.37%
vs
+9.48%
6 mth
+2.01%
vs
+6.03%
1 yr
-9.12%
vs
+4.8%
3 yr
+175.51%
vs
+61.59%
5 yr
+171.71%
vs
+139.96%
Zydus Lifesciences Ltd Top mutual funds holding
arrow
Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), a Company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations.
personal

Grow your wealth with more research recommendations

+91